Can a traditional chinese herb normalize breast cancer markers?

NCT ID NCT05871437

Not yet recruiting Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether Huaier granules, a traditional Chinese medicine, can help reduce elevated tumor markers (CEA, CA125, CA153) to normal levels in people with early-stage breast cancer. About 232 participants will take the granules daily for a year alongside standard care. The goal is to see if the treatment improves marker recovery rates and is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Huaier granules (a traditional Chinese medicine extract)
What this could lead to: If successful, this could show that Huaier granules help normalize tumor markers in early breast cancer, potentially offering a complementary therapy to standard care.
What could go wrong: This is an early-phase trial with a modest size (232 people). It focuses on tumor marker levels, not long-term survival or recurrence, so benefits may not translate to better outcomes. Side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.